Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
GLMD
#4053
Galmed Pharmaceuticals Ltd.
0.6
1
-7.58%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
-7.58%
Variazione Mensile
-28.24%
Variazione di 6 mesi
-56.74%
Variazione Annuale
-72.27%
Chiusura Precedente
0.6
6
Open
0.6
1
Bid
Ask
Low
0.6
1
High
0.6
1
Volume
2
Mercati
Mercato Azionario Statunitense
Salute
GLMD
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
1.65 M
2.35 M
Valuation ratios
Enterprise value
577.63 K
—
Price to earnings ratio
0.39
—
Price to sales ratio
—
—
Price to cash flow ratio
0.5
—
Price to book ratio
0.18
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
-0.19
-0.85
Return on equity %
-0.21
-1.02
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
7.42
23.13
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
0.05
0.16
Long term debt to total equity ratio
0.05
0.19
Per share metrics
Operating cash flow per share
-3.71
-105.21
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
12.78
411.18
Net current asset value per share
17.32
443.93
Tangible book value per share
17.54
396.94
Working capital per share
14.99
364.51
Book value per share
17.54
396.94
Notizie
Galmed Pharmaceuticals convoca assemblea straordinaria per il 4 marzo
Galmed Pharmaceuticals schedules special shareholder meeting for March 4
Galmed Pharmaceuticals riceve avviso da Nasdaq sul prezzo minimo di offerta
Galmed Pharmaceuticals receives Nasdaq minimum bid price notice
Galmed presenterà dati sul potenziale di Aramchol nel cancro al fegato
Galmed to present data on Aramchol’s potential in liver cancer
Azioni Galmed in rialzo dopo concessione brevetto per terapia combinata MASH
Galmed stock rises after patent grant for MASH combo therapy
Galmed ottiene brevetto in Corea del Sud per terapia combinata
Galmed receives patent for combination therapy in South Korea
Il titolo di Galmed Pharmaceuticals sale grazie alle prospettive ottimistiche del CEO
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook